EA201591598A1 - DERIVATIVES OF URIDINE NUCLEOSIDES, COMPOSITIONS AND METHODS OF APPLICATION - Google Patents
DERIVATIVES OF URIDINE NUCLEOSIDES, COMPOSITIONS AND METHODS OF APPLICATIONInfo
- Publication number
- EA201591598A1 EA201591598A1 EA201591598A EA201591598A EA201591598A1 EA 201591598 A1 EA201591598 A1 EA 201591598A1 EA 201591598 A EA201591598 A EA 201591598A EA 201591598 A EA201591598 A EA 201591598A EA 201591598 A1 EA201591598 A1 EA 201591598A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- derivatives
- compositions
- methods
- application
- uridine nucleosides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Данное описание изобретения относится к производным уридиновых нуклеозидов, к композициям, содержащим терапевтически эффективные количества этих нуклеозидных производныхб и к способам использования этих нуклеозидных производных или композиций в лечении нарушений, которые чувствительны к лигандам, таким как агонисты, рецептора PY, например нейрональных нарушений, включая нейродегенеративные нарушения (например, болезнь Альцгеймера, болезнь Паркинсона) и травматическое повреждение ЦНС, боль, синдром Дауна (DS), глаукому и воспалительные состояния.This disclosure relates to derivatives of uridine nucleosides, compositions containing therapeutically effective amounts of these nucleoside derivatives, and methods of using these nucleoside derivatives or compositions in treating disorders that are sensitive to ligands, such as agonists, of the PY receptor, such as neuronal disorders, including neurodegenerative disorders (such as Alzheimer's disease, Parkinson’s disease) and traumatic CNS damage, pain, Down syndrome (DS), glaucoma, and inflammatory state.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361780219P | 2013-03-13 | 2013-03-13 | |
US201361883604P | 2013-09-27 | 2013-09-27 | |
PCT/US2014/026865 WO2014160502A1 (en) | 2013-03-13 | 2014-03-13 | Uridine nucleoside derivatives, compositions and methods of use |
Publications (3)
Publication Number | Publication Date |
---|---|
EA201591598A1 true EA201591598A1 (en) | 2016-03-31 |
EA034135B1 EA034135B1 (en) | 2020-01-09 |
EA034135B9 EA034135B9 (en) | 2020-04-10 |
Family
ID=51625444
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201591598A EA034135B9 (en) | 2013-03-13 | 2014-03-13 | Pharmaceutical compositions based on uridine nucleoside derivatives as pyreceptor agonists |
Country Status (19)
Country | Link |
---|---|
US (3) | US10544183B2 (en) |
EP (2) | EP2968385B1 (en) |
JP (1) | JP6591957B2 (en) |
KR (1) | KR102304242B1 (en) |
CN (1) | CN105407898B (en) |
AU (1) | AU2014243707B2 (en) |
CA (1) | CA2904180C (en) |
DK (1) | DK2968385T3 (en) |
EA (1) | EA034135B9 (en) |
ES (1) | ES2684368T3 (en) |
HK (1) | HK1220388A1 (en) |
HU (1) | HUE039871T2 (en) |
IL (1) | IL241172B (en) |
PL (1) | PL2968385T3 (en) |
PT (1) | PT2968385T (en) |
SI (1) | SI2968385T1 (en) |
TW (1) | TWI640533B (en) |
WO (1) | WO2014160502A1 (en) |
ZA (1) | ZA201507045B (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2850367C (en) | 2011-09-30 | 2021-06-01 | Tufts University | Uridine diphosphate derivatives, compositions and methods for treating neurodegenerative disorders |
EP2900680A4 (en) | 2012-09-28 | 2016-06-08 | Univ Tufts | Uridine diphosphate derivatives, prodrugs, compositions and uses thereof |
JP6591957B2 (en) | 2013-03-13 | 2019-10-16 | タフツ・ユニバーシティ | Uridine nucleoside derivatives, compositions and methods of use |
AR095442A1 (en) | 2013-03-13 | 2015-10-14 | Univ Tufts | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE |
WO2017185061A1 (en) | 2016-04-21 | 2017-10-26 | Astrocyte Pharmaceuticals, Inc. | Compounds and methods for treating neurological and cardiovascular conditions |
JP7311855B2 (en) | 2018-02-09 | 2023-07-20 | アストロサイト ファーマシューティカルズ, インコーポレイテッド | Compounds and methods for treating addiction and related disorders |
BR112021005290A2 (en) | 2018-09-26 | 2021-06-22 | Astrocyte Pharmaceuticals, Inc. | polymorphic compounds and their uses |
US20220195056A1 (en) * | 2019-08-07 | 2022-06-23 | Icahn School Of Medicine At Mount Sinai | Method of treating keloids |
WO2022089612A1 (en) * | 2020-10-30 | 2022-05-05 | 上海岸阔医药科技有限公司 | Use of uridine derivative in preparation of medicament |
WO2022266027A1 (en) * | 2021-06-15 | 2022-12-22 | Steven Baranowitz | Prevention and treatment of post-infection neurological disorders and clotting/thrombotic disorders |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0621073B2 (en) | 1986-03-06 | 1994-03-23 | 日水製薬株式会社 | Central depressant |
JP3032053B2 (en) | 1991-09-06 | 2000-04-10 | 日水製薬株式会社 | Uridine derivatives and pharmaceuticals containing the same |
US5962459A (en) | 1996-05-28 | 1999-10-05 | Polifarma S.P.A. | Therapeutic active agent for treatment of neuron degenerative diseases |
WO1999009998A1 (en) * | 1997-08-29 | 1999-03-04 | The University Of North Carolina At Chapel Hill | Use of uridine 5'-diphosphate and analogs thereof for the treatment of lung diseases |
US20070004670A1 (en) | 1998-07-31 | 2007-01-04 | Richard Wurtman | Compositions containing citicoline, and methods of use thereof |
ATE446097T1 (en) | 1998-07-31 | 2009-11-15 | Massachusetts Inst Technology | USE OF URIDINE IN COMBINATION WITH CHOLINE TO TREAT MEMORY DISORDERS |
US20050203053A1 (en) | 1999-07-30 | 2005-09-15 | Wurtman Richard J. | Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function |
US8518882B2 (en) | 1998-07-31 | 2013-08-27 | Massachusetts Institute Of Technology | Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same |
US20060069061A1 (en) | 1998-07-31 | 2006-03-30 | Dick Wurtman | Compositions containing uridine and choline, and methods utilizing same |
US8143234B2 (en) | 1998-07-31 | 2012-03-27 | Massachusetts Institute Of Technology | Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function |
US8314064B2 (en) | 1998-07-31 | 2012-11-20 | Massachusetts Institute Of Technology | Uridine administration stimulates membrane production |
GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
US6875751B2 (en) | 2000-06-15 | 2005-04-05 | Idenix Pharmaceuticals, Inc. | 3′-prodrugs of 2′-deoxy-β-L-nucleosides |
CA2444161A1 (en) | 2003-10-01 | 2005-04-01 | Japan Health Sciences Foundation | A screening method of drug for treatment of neuropathic pain |
WO2005122767A1 (en) | 2004-06-10 | 2005-12-29 | Mclean Hospital Corporation | Pyrimidines, such as uridine, in treatments for patients with bipolar disorder |
JP2008513453A (en) * | 2004-09-15 | 2008-05-01 | マサチューセッツ インスティテュート オブ テクノロジー | Compositions containing uridine and methods of use thereof |
CN101237772A (en) * | 2005-06-29 | 2008-08-06 | 印斯拜尔药品股份有限公司 | P2Y6 receptor agonists for treating lung diseases |
US7851456B2 (en) | 2005-06-29 | 2010-12-14 | Inspire Pharmaceuticals, Inc. | P2Y6 receptor agonists for treating lung diseases |
WO2008115499A1 (en) | 2007-03-19 | 2008-09-25 | State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The University Of Oregon | Mannich base n-oxide drugs |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
EP3587434A1 (en) | 2008-09-23 | 2020-01-01 | Alnylam Pharmaceuticals Inc. | Chemical modifications of monomers and oligonucleotides with click components for conjugation with ligands |
IT1398378B1 (en) | 2010-02-22 | 2013-02-22 | Omikron Italia S R L | CYTICOLINE FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION. |
EP2646449B1 (en) * | 2010-12-01 | 2015-08-19 | Bar-Ilan University | Uridine di- or tri-phosphate derivatives and uses thereof |
CA2850367C (en) * | 2011-09-30 | 2021-06-01 | Tufts University | Uridine diphosphate derivatives, compositions and methods for treating neurodegenerative disorders |
EP2900680A4 (en) | 2012-09-28 | 2016-06-08 | Univ Tufts | Uridine diphosphate derivatives, prodrugs, compositions and uses thereof |
AR095442A1 (en) * | 2013-03-13 | 2015-10-14 | Univ Tufts | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE |
JP6591957B2 (en) | 2013-03-13 | 2019-10-16 | タフツ・ユニバーシティ | Uridine nucleoside derivatives, compositions and methods of use |
-
2014
- 2014-03-13 JP JP2016502267A patent/JP6591957B2/en not_active Expired - Fee Related
- 2014-03-13 TW TW103109174A patent/TWI640533B/en active
- 2014-03-13 KR KR1020157028543A patent/KR102304242B1/en active IP Right Grant
- 2014-03-13 CN CN201480023822.XA patent/CN105407898B/en not_active Expired - Fee Related
- 2014-03-13 WO PCT/US2014/026865 patent/WO2014160502A1/en active Application Filing
- 2014-03-13 EP EP14775026.9A patent/EP2968385B1/en active Active
- 2014-03-13 HU HUE14775026A patent/HUE039871T2/en unknown
- 2014-03-13 AU AU2014243707A patent/AU2014243707B2/en not_active Ceased
- 2014-03-13 SI SI201430843T patent/SI2968385T1/en unknown
- 2014-03-13 EA EA201591598A patent/EA034135B9/en unknown
- 2014-03-13 US US14/775,426 patent/US10544183B2/en not_active Expired - Fee Related
- 2014-03-13 CA CA2904180A patent/CA2904180C/en active Active
- 2014-03-13 PT PT14775026T patent/PT2968385T/en unknown
- 2014-03-13 ES ES14775026T patent/ES2684368T3/en active Active
- 2014-03-13 DK DK14775026.9T patent/DK2968385T3/en active
- 2014-03-13 EP EP18173639.8A patent/EP3449925B1/en active Active
- 2014-03-13 PL PL14775026T patent/PL2968385T3/en unknown
-
2015
- 2015-09-03 IL IL241172A patent/IL241172B/en active IP Right Grant
- 2015-09-22 ZA ZA2015/07045A patent/ZA201507045B/en unknown
-
2016
- 2016-07-19 HK HK16108533.9A patent/HK1220388A1/en not_active IP Right Cessation
-
2020
- 2020-01-27 US US16/773,406 patent/US11124536B2/en active Active
-
2021
- 2021-08-12 US US17/400,515 patent/US20220135611A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201591598A1 (en) | DERIVATIVES OF URIDINE NUCLEOSIDES, COMPOSITIONS AND METHODS OF APPLICATION | |
PH12018502125A1 (en) | Bipyrazole derivatives as jak inhibitors | |
MX2023008994A (en) | Fused pyrazine derivatives as a2a / a2b inhibitors. | |
BR112015009942A2 (en) | tricyclic fused thiophene derivatives as jak inhibitors | |
EA201792529A1 (en) | Thyrosine Kinase Inhibitors | |
IN2014CN03043A (en) | ||
TR201901886T4 (en) | DNA-PK inhibitors. | |
EA201690618A1 (en) | BLUTON TYROSINKINASE INHIBITORS | |
EA201692177A1 (en) | CONNECTIONS AND COMPOSITIONS AS AN AGONISTS OF TOLL-LIKE RECEPTOR 7 | |
MA41251B1 (en) | Thieno [2,3-c] pyrrol-4-one derivatives as erk inhibitors | |
EA201892745A1 (en) | PHOSPHORAMIDATE DERIVATIVES OF NUCLEOSIDE AS ANTI-TREATMENT AGENTS | |
EA201491592A1 (en) | CONNECTIONS OF INDOLS AND INDAZOLS ACTIVATING AMPK | |
MX2018016419A (en) | N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors. | |
UY37466A (en) | N-HYDROXIAMIDINHETEROCICLES SUBSTITUTED AS MODULATORS OF INDOLAMINE 2,3-DIOXYGENASE | |
PL410665A1 (en) | Arginase inhibitors and their therapeutical applications | |
WO2015051284A3 (en) | Small molecule securinine and norsecurinine analogs and their use in cancers inflammatory diseases and infections | |
EA201690376A1 (en) | DEOXICITIDINKINASE INHIBITORS | |
EA201791881A1 (en) | DERIVATIVES OF 2-AMINOPYRIDINE AS ANTAGONISTS OF Adenosine A receptor A And Melatonin MT Receptors Ligands | |
MX367707B (en) | Compounds for use in prevention and treatment of neurodegenerative diseases and pain. | |
EA201500736A1 (en) | PYRAZOLILKARBOXAMIDA I AS CRAC CHANNEL INHIBITORS | |
EA201500737A1 (en) | PYRAZOLILKARBOXAMIDA II AS CRAC CHANNEL INHIBITORS | |
IT201600130012A1 (en) | Composition for use in the treatment of disorders of the urogenital system | |
EA201592120A1 (en) | COMPOSITION BASED ON NANOPARTICLES CONTAINING ANTAGONIST TRPA1 | |
IN2013CH01199A (en) | ||
EA202190204A1 (en) | CONDENSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TH4A | Publication of the corrected specification to eurasian patent |